DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Bioavailability Study of Tranylcypromine 10mg Tablets Under Fasting Conditions

Information source: Par Pharmaceutical, Inc.
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: To Determine the Bioavailability of Tranylcypromine

Intervention: Tranylcypromine (Drug); Parnate (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: Par Pharmaceutical, Inc.

Official(s) and/or principal investigator(s):
Antonio Pizzaro, Principal Investigator, Affiliation: SFBC Ft. Myers, Inc


To compare the single-dose Bioavailability of Tranylcypromine and Parnate

Clinical Details

Official title: To Compare Bioavailability of Kali Tranylcypromine 10mg Tablets to That of Parnate 10 mg Tablets Under Fasting Conditions.

Study design: Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label

Primary outcome: Rate and Extend of Absorption

Detailed description: To compare the relative Bioavailability of Tranylcypromine 10 mg tablets with that of PARNATE 10mg tablets in normal,healthy, men and women under fasting conditions


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Subjects will be normal, healthy adult men and women who volunteer to participate.

- Is the individual healthy, nonsmoking, normal adult man or woman who volunteers to


- Is s/he at least 18 years of age? Is his/her BMI between 19 and 30, exclusive?

- Is she willing to avoid pregnancy by abstaining from sexual intercourse, or by the

use of barrier methods. (diaphragm, condom, foams/jellies, sponge), and IUD, or has she has been surgically sterile or post- menopausal at least six months prior to entering into the study?

- Is s/he considered reliable and capable of understanding his/her responsibility and

role in the study?

- Has/s/he provided written informed consent?

- A no answer to any of the above questions indicates taht the individual is ineligible

for enrollment. Exclusion Criteria:

- Does the individual have a history of allergy or hypersensitivity to tranylcypromine?

- Does/ s/he have clinically significant laboratory abnormalities that would interface

with the conduct or interpretation of the study or jeopardize his/her safety?

- Does s/he have significant history or clinical evidence of auto-immune,

cardiovascular, gastrointestinal, hematopoietic, hepatic, neurological, ongoing infection, pancreatic, or renal diseases that would interface with the conduct or interpretation of the study or jeopardize his/her safety?

- Is she nursing?

- Does s/he have serious psychological illness?

- Does s/he have significant history ( within the past year) or clinical evidence of

alcohol or drug abuse?

- Does s/he have a positive urine drug screen or saliva alcohol screen, or a positive

HIV-1 , or hepatitis B or C screen, or a positive pregnancy test?-Is s/he unable to refrain from the use of alcohol or xanthine-containing foods or beverages during periods beginning 48 hours prior to study drug administration and ending when the alst blood sample has been taken?

- Is s/he unable to refrain from the ingestion of smoked meat, cheese (except cream

cheese and cottage cheese), wine and beer during periods beginning 48 hours prior to study initiation and ending seven days after the last blood sample has been taken in study period two?

- Has s/he used any prescription drug during the 14-day period prior to study

initiation, or any OTC drug during the 72-hour period preceding study initiation?

- Is s/he unable to refrain from the use of all concomitant medications during the


- Ha s/he donated or lost blood, or participated in a clinical study which involved the

with drawl of a large volume of blood (480mL or more), during the six week period preceding study initiation?

- Has s/he donated an investigational drug during the 30 day period preceding study


- A yes answer to any of the above questions indicates that the individual is

ineligible for enrollment.

Locations and Contacts

SFBC Ft. Myers, Inc, Ft. Myers, Florida 33901, United States
Additional Information

Starting date: October 2004
Last updated: April 3, 2008

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017